After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...